Pharma major Lupin has been granted an extension to set up its state-of-the-art formulation manufacturing unit at the MIHAN Special Economic Zone (SEZ) in Nagpur from the Commerce Ministry. However, a final call on the matter is yet to be taken by the Board of Approval (BoA) for SEZs.
Lupin had sought the extension on the grounds that it is yet to receive approvals from the US Food and Drug Administration (USFDA) for drugs that are to be produced at the unit. The company received the letter-of-permission (LoP) for setting up its unit in the MIHAN SEZ in April 2012, but has not been able to start commercial operations.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: